HLA不相容活体供肾移植对比等待或HLA相容尸体供肾移植的生存获益
HLA不相容LDKT组患者生存率显著优于两对照组,且在各供者特异性抗体强度下均有生存获益,提示在DDKT等待时间长的国家可作为致敏患者的选择。
要点
- HLA不相容活体供肾移植在韩国致敏肾衰竭患者中显示患者生存获益
- 该获益在仅等待名单组及等待或HLA相容DDKT组中均显著
- 各供者特异性抗体强度下均观察到显著生存获益
核心结论
- HLA不相容活体供肾移植相比等待HLA相容尸体供肾移植或接受HLA相容尸体供肾移植,在韩国患者中具有生存获益。
- 该结果提示在尸体供肾等待时间长的国家,HLA不相容活体供肾移植可作为致敏肾衰竭患者的良好选择。
研究设计与样本
- 与HLA不相容活体供肾移植组匹配的对照组各930例,分别为仅等待名单组与等待或HLA相容尸体供肾移植组。
主要发现
- HLA不相容活体供肾移植组患者生存率显著优于仅等待名单组。
- HLA不相容活体供肾移植组患者生存率显著优于等待或HLA相容尸体供肾移植组。
- HLA不相容活体供肾移植组在所有供者特异性抗体强度下均显示显著生存获益。
临床怎么用
- 对致敏且尸体供肾等待时间长的肾衰竭患者,可考虑将HLA不相容活体供肾移植作为增加移植机会并可能改善生存的策略。
局限性
- 研究为韩国两家医院的经验,结论外推需结合当地等待时间与脱敏方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA-incompatible living donor kidney transplantation (LDKT) is one of efforts to increase kidney transplantation opportunity for sensitized patients with kidney failure. However, there are conflicting reports for outcomes of HLA-incompatible kidney transplantation compared to patients who wait for HLA-compatible deceased donor kidney transplantation (DDKT) in the United States and United Kingdom. Waiting for an HLA-compatible DDKT is relatively disadvantageous in Korea, because the average waiting time is more than five years. To study this further, we compared outcomes of HLA-incompatible LDKT with those who wait for HLA-compatible DDKT in Korea. One hundred eighty nine patients underwent HLA-incompatible LDKT after desensitization between 2006 and 2018 in two Korean hospitals (42 with a positive complement-dependent cytotoxicity cross-match, 89 with a positive flow cytometric cross-match, and 58 with a positive donor-specific antibody with negative cross-match). The distribution of matched variables was comparable between the HLA-incompatible LDKT group and the matched control groups (waiting-list-only group; and the waiting-list-or-HLA-compatible-DDKT groups; 930 patients each). The HLA-incompatible LDKT group showed a significantly better patient survival rate compared to the waiting-list-only group and the waiting-list-or-HLA-compatible-DDKT groups. Furthermore, the HLA-incompatible LDKT group showed a significant survival benefit as compared with the matched groups at all strength of donor-specific antibodies. Thus, HLA-incompatible LDKT could have a survival benefit as compared with patients who were waitlisted for HLA-compatible DDKT or received HLA-compatible DDKT in Korea. This suggests that HLA-incompatible LDKT as a good option for sensitized patients with kidney failure in countries with prolonged waiting times for DDKT.
引用
- Koo TY, Lee JH, Min SI, et al. Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time. Kidney Int. 2021. PMID: 33647326. doi:10.1016/j.kint.2021.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。